3.58
-0.07 (-2.05%)
| Penutupan Terdahulu | 3.65 |
| Jumlah Dagangan | 341,335 |
| Harga / Jualan (P/S) | 31.25 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -227.21% |
| EPS Cair (TTM) | -2.10 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 155.40% |
| Nisbah Semasa (MRQ) | 1.98 |
| Aliran Tunai Operasi (OCF TTM) | -28.85 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -3.22 M |
| Pulangan Atas Aset (ROA TTM) | -45.36% |
| Pulangan Atas Ekuiti (ROE TTM) | -167.55% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Opus Genetics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | -2.5 |
| Persekitaran Makro | -0.3 |
| AI Insight | NA |
| Purata | -0.11 |
|
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 21.20% |
| % Dimiliki oleh Institusi | 24.41% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |